<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02278393</url>
  </required_header>
  <id_info>
    <org_study_id>NU360</org_study_id>
    <nct_id>NCT02278393</nct_id>
  </id_info>
  <brief_title>A Clinical Study for Evaluating the Safety of a Plant Sterol-enriched Fermented Dairy Product in Japanese Healthy Adults</brief_title>
  <official_title>A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL STUDY TO EVALUATE THE SAFETY OF EXCESSIVE CONSUMPTION OF PLANT STEROL-ENRICHED FERMENTED DAIRY PRODUCT OVER A 4-WEEK PERIOD IN JAPANESE HEALTHY ADULTS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Danone Japan</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Danone Research</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Investigate the safety of excessive consumption of plant sterol-enriched fermented dairy&#xD;
      product over a 4-week period in Japanese healthy adults&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2014</start_date>
  <completion_date type="Actual">May 2014</completion_date>
  <primary_completion_date type="Actual">May 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>From baseline to 6 weeks (4-week consumption + 2-week follow-up periods)</time_frame>
    <description>Number of subjects with at least one adverse event by study group</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>From baseline to 6 weeks (4-week consumption + 2-week follow-up periods)</time_frame>
    <description>Number of adverse events by study group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital signs</measure>
    <time_frame>From baseline to 6 weeks (4-week consumption + 2-week follow-up periods)</time_frame>
    <description>Descriptive statistics for systolic and diastolic blood pressure, heart rate and BMI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital signs</measure>
    <time_frame>From baseline to 6 weeks (4-week consumption + 2-week follow-up periods)</time_frame>
    <description>To assess the change for systolic and diastolic blood pressure, heart rate and BMI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory measurements</measure>
    <time_frame>From baseline to 6 weeks (4-week consumption + 2-week follow-up periods)</time_frame>
    <description>Descriptive statistics for Haematology parameters, liver/kidney/muscle function parameters, carbohydrate metabolism parameters, lipids, minerals, proteins and electrolytes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory measurements</measure>
    <time_frame>From baseline to 6 weeks (4-week consumption + 2-week follow-up periods)</time_frame>
    <description>To assess the change for Haematology parameters, liver/kidney/muscle function parameters, carbohydrate metabolism parameters, lipids, minerals, proteins and electrolytes</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">84</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>1-Fermented Dairy Product with Phytosterols (test)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>one arm active = 3 bottles of test product/day with 1,6g of phytosterols each</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2-Fermented dairy Product with No Phytosterols (control)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>one arm control product= 3 bottles test productl/day with no Phytosterols</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>1-Fermented Dairy Product with Phytosterols (test)</intervention_name>
    <description>1- 3 bottles of test product/day</description>
    <arm_group_label>1-Fermented Dairy Product with Phytosterols (test)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>2-Fermented dairy Product with No Phytosterols (control)</intervention_name>
    <description>2-3 bottles of control product/day</description>
    <arm_group_label>2-Fermented dairy Product with No Phytosterols (control)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  To be checked at the inclusion visit (V1) :&#xD;
&#xD;
          -  II 01: Male/female subject, aged from 20 to 55 years (bounds included).&#xD;
&#xD;
          -  II 02: Subject with body mass index (BMI) between 18.5 kg/m2 (bound included) and 30&#xD;
             kg/m2 (bound excluded).&#xD;
&#xD;
          -  II 03: Subject with LDL-cholesterol plasma level under 140 mg/dL (3.6 mmol/L) (bound&#xD;
             excluded).&#xD;
&#xD;
          -  II 04: Subject with triglycerides under 200 mg/dL (2.3 mmol/L) (bound included).&#xD;
&#xD;
          -  II 05: Non hypertensive subject defined with Systolic Blood Pressure (SBP) &lt;140mmHg&#xD;
             and Diastolic Blood Pressure (DBP) &lt;90 mmHg.&#xD;
&#xD;
          -  II 06: Subject agreeing not to consume any supplements/excessive plant sterols and&#xD;
             plant stanols in any form during the study period.&#xD;
&#xD;
          -  II 07: If of childbearing potential, female subject must be using or complying with&#xD;
             one of the following medically approved methods of contraception such as, but not&#xD;
             exclusively:&#xD;
&#xD;
          -  Oral birth control pills (at least 1 full monthly cycle prior to study product&#xD;
             administration);&#xD;
&#xD;
          -  Intra-uterine device (IUD);&#xD;
&#xD;
          -  Double barrier methods (such as condoms and spermicide); OR female subject must be&#xD;
             postmenopausal for at least 12 months prior to trial entry or surgically sterile (i.e.&#xD;
             hysterectomy, bilateral oophorectomy or bilateral tubal ligation).&#xD;
&#xD;
          -  II 08: Subject covered by social security or covered by similar system.&#xD;
&#xD;
          -  II 09: Subject, upon briefing of the content of the present study, fully understanding&#xD;
             and agreeing to its objective; and being able to personally sign a written informed&#xD;
             consent.&#xD;
&#xD;
          -  II 10: Subject having given written (dated and signed) inform consent to take part in&#xD;
             the study.&#xD;
&#xD;
          -  II 11: Asian subjects originating from Japan&#xD;
&#xD;
          -  II12: Subject who is able to communicate well with the investigator and to comply with&#xD;
             the requirements of the entire study.&#xD;
&#xD;
          -  II13: Subject having a fridge at home for study products storage with sufficient&#xD;
             capacity.&#xD;
&#xD;
        To be checked at the randomization visit (V2):&#xD;
&#xD;
        - RI 01: Subject having followed the dietary recommendations over the wash-out period.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  To be checked at the inclusion visit (V1):&#xD;
&#xD;
          -  IE 01: Subject having experienced any cardiovascular event (cardiac infarction, angina&#xD;
             attack, surgical or endoscopic coronary angioplasty, stroke, arterial disease, etc.).&#xD;
&#xD;
          -  IE 02: Subject suffering from any serious or chronic liver, renal, cardiovascular,&#xD;
             respiratory, endocrine or metabolic disorders.&#xD;
&#xD;
          -  IE 03: Subject with gastro-intestinal disorders (such as diarrhoea, constipation,&#xD;
             irritable bowel syndrome) or using laxatives.&#xD;
&#xD;
          -  IE 04: Subject with diabetes Type I and Type II or Fasting Blood Sugar test (FBS) &gt;&#xD;
             125 mg/dL at screening visit.&#xD;
&#xD;
          -  IE 05: Subject with active liver disease or hepatic dysfunction as defined by&#xD;
             elevations in liver enzymes: [alanine aminotransferase (ALT), aspartate&#xD;
             aminotransferase (AST), gamma glutamyl transferase (GGT) &gt; 3X the upper limit of&#xD;
             normal (ULN).&#xD;
&#xD;
          -  IE 06: Subject with unexplained serum creatine phosphokinase (CPK) &gt; 2X the upper&#xD;
             limit of normal (ULN). Subject with a reason for CPK elevation may continue in&#xD;
             inclusion process and have the measurement repeated prior to randomization; a repeat&#xD;
             CPK &gt; 2X ULN is exclusionary.&#xD;
&#xD;
          -  IE 07: Subject with weight change (variation &gt; 5%) within 6 months at least prior to&#xD;
             inclusion.&#xD;
&#xD;
          -  IE 08: Subject taking any hypocholesterolemic drugs or products (statins, ezetimibe,&#xD;
             sequesterants, niacin, nicotinates, probucol, omega-3 fatty acids (EPA-DHA, ALAâ€¦), and&#xD;
             fibrates).&#xD;
&#xD;
          -  IE 09: Subjects having stopped their hypocholesterolemic drugs or products for less&#xD;
             than 3 months&#xD;
&#xD;
          -  IE 10: Subject with known lactose intolerance.&#xD;
&#xD;
          -  IE 11: Subject with known allergy or hypersensitivity to plant sterols and to any&#xD;
             component of the study product (milk protein for example).&#xD;
&#xD;
          -  IE 12: Subjects having sitosterolemia.&#xD;
&#xD;
          -  IE 13: Subject who had any surgery or intervention requiring a general anaesthesia in&#xD;
             the preceding 4 weeks, or who plans to have one during the course of the study.&#xD;
&#xD;
          -  IE 14: Subject receiving (currently or in the 4 last weeks) systemic treatment or&#xD;
             topical treatment likely to interfere with evaluation of the study parameters.&#xD;
&#xD;
          -  IE 15: Subject involved in any other clinical study within the preceding month or in&#xD;
             the exclusion period after another clinical study.&#xD;
&#xD;
          -  IE 16 Subject having blood sample of 200 mL or more taken (e.g., donated blood) within&#xD;
             1 month, or 400 mL or more within 3 months before the start of the present study.&#xD;
&#xD;
          -  IE 17: Subject with heavy alcohol intake (&gt; 60 g/day).&#xD;
&#xD;
          -  IE 18: Subject taking any treatment for anorexia, weight loss, or any form of&#xD;
             treatment likely to interfere with metabolism or dietary habits (e.g. hypolipemic,&#xD;
             hypoglycaemic treatments).&#xD;
&#xD;
          -  IE 19: For female subject: pregnant woman or woman planning to become pregnant during&#xD;
             the study; breast-feeding woman.&#xD;
&#xD;
          -  IE 20: For female subject: subject likely to change her contraceptive method or&#xD;
             hormone replacement therapy during the study.&#xD;
&#xD;
          -  IE 21: Subject in a situation, which in the investigator's opinion could interfere&#xD;
             with optimal participation in the present study (e.g. -products consumer) or could&#xD;
             constitute a special risk for the subject.&#xD;
&#xD;
          -  IE 22: Subject who is susceptible to not comply with dietary qualitative restriction&#xD;
             during the study period.&#xD;
&#xD;
          -  IE 23 Vulnerable subjects defined as individuals whose willingness to volunteer in the&#xD;
             clinical trial may be unduly influenced by the expectation, whether justified or not,&#xD;
             of benefits associated with participation, or of a retaliatory response from senior&#xD;
             members of a hierarchy in case of refusal to participate. Examples are members of a&#xD;
             group with a hierarchical structure, such as medical, pharmacy, dental and nursing&#xD;
             students, subordinate hospital and laboratory personnel, employees of the&#xD;
             pharmaceutical industry, members of the armed forces, and persons kept in detention.&#xD;
&#xD;
          -  IE 24: Subject expected to be living in the same home as a current participating&#xD;
             subject and to concomitantly receive some study products.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christine MRINI, MD, PHD</last_name>
    <role>Study Director</role>
    <affiliation>Danone Research Life Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Yaesu Sakura-dori Clinic</name>
      <address>
        <city>Tokyo</city>
        <zip>103-0028</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>October 2014</verification_date>
  <study_first_submitted>October 16, 2014</study_first_submitted>
  <study_first_submitted_qc>October 29, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 30, 2014</study_first_posted>
  <last_update_submitted>October 29, 2014</last_update_submitted>
  <last_update_submitted_qc>October 29, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 30, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Japanese healthy volunteers</keyword>
  <keyword>High LDL-C</keyword>
  <keyword>dairy drinks</keyword>
  <keyword>phytosterols</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

